An interventional study of Whole brain radiation and Stereotactic radiation (SRS) in Brain Metastases, sponsored by Brigham and Women's Hospital. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Treatment
Aizer AA, Shin KY, Catalano PJ, Ricca I, Johnson M, Benham G, Roper K, Spicer B, Mann E, Nosker J, Parsons MW, Mendu ML, Hepel J, Chipidza F, Krishnan M, Shi D…PubMed 41712219 ↗; 3 more
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,447 studies in Brain Neoplasms with a site in United States — 233 open to participants now, 355 under way, 18 of them phase 3. Brain Neoplasms · United States.
Among the 1,447 studies in Brain Neoplasms with a site in United States, this one is the 80th largest by enrollment of the 1,192 interventional ones that give a count, is one of 64 that started in 2017, is one of 226 with no phase, reaches primary completion later than 15 of the 353 other live ones, and was the 946th registered.
2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.
Browse Brain Neoplasms studies →233 of the 1,447 studies in Brain Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Brian J.Gill · Sites in United States
Ages 22–65
Stanford University · Sites in United States
Ages 6 mo–25 yrs
University of California, San Francisco · Sites in United States
Ages 18+
Beijing Inno Medicine Co., Ltd. · Sites in United States, China
Ages 18–70
University of Florida · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,447 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 554 · Phase 2 522 · Phase 3 72 · Phase 4 18
First in 1979; this study’s year is marked. 64 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 196 is above the median of 40 across 1,838 interventional studies indexed under Brain Neoplasms.
Median enrollment 30 across the 1,192 interventional studies, 76 across the 191 observational. Of the 994 that completed or were terminated, 355 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
221 of 1,447 have an industry lead sponsor. The 10 most frequent:
Brigham and Women's Hospital is the lead sponsor of 1,270 studies on the registry; 230 are open to participants now.
Of its 117 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.
Brigham and Women's Hospital has 6 studies filed under Brain Neoplasms — fewer than ten, so there is no comparison to draw.
140 of the studies in Brain Neoplasms with a site in United States that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00978458Phase 3Eastern Cooperative Oncology GroupRadiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma | 2026-12-31 |
| NCT03741673Phase 3M.D. Anderson Cancer CenterPre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases | 2027-01-31 |
| NCT05438212Phase 3NRG OncologyComparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases | 2027-03-16 |
| NCT05271240Phase 3Northwell HealthRepeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | 2027-04-01 |
| NCT00950001Phase 3M.D. Anderson Cancer CenterStereotactic Radiosurgery Compared to Observation in Treating Patients With Brain Metastases | 2027-04-30 |
Add all 140 to your calendar (.ics) → With an account.
Among the 1,447 studies in Brain Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This research study is studying two different types of radiation as treatment for brain metastases (tumors in the brain that spread from a cancer that originated elsewhere in the body)
This research study is a Phase III clinical trial. Phase III clinical trials examine the safety and effectiveness of a treatment, often comparing it to another known treatment. In this case, the investigators are specifically looking at differences between two forms of radiation treatment in terms of subsequent quality of life.
In this research study, the investigators are comparing stereotactic (focused, pinpoint) radiation (in which each tumor is narrowly targeted) against whole brain radiation (radiation targeting the entire brain) in the treatment of brain metastases. Currently whole brain radiation is the standard option for patients with 5-20 brain metastases. Stereotactic radiation is the standard option for patients with 1-4 brain metastases. Among patients with 1-4 brain metastases, recently published studies suggest that stereotactic radiation results in fewer neurologic side effects than whole brain radiation. It also yields better quality of life in this population. It remains unknown whether stereotactic radiation improves quality of life in patients with 5-20 brain metastases relative to whole brain radiation. In this study, the investigators seek to determine which of the two methods of study treatment results in a better subsequent quality of life for patients with 5-20 brain metastases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* MRI will be performed prior to radiation is administered * A hippocampal sparing approach will be used when possible * Dose will be 30 Gy in 10 fractions
Radiation: Whole brain radiation
* MRI will be performed prior to radiation is administered * Radiation will be given in 1-5 fractions (dose depends on the size of the tumor that will be treated)
Radiation: Stereotactic radiation (SRS)
Treatment of the whole brain with radiation. When possible the hippocampus will be spared from radiation.
Focused radiation to each individual brain metastasis without treatment of the remainder of the brain.
Change in MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT) Score
Questionnaire - MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT). Results reflect patient-reported symptoms. Here they are presented as a mean change: the difference in the weighted mean of symptom severity and interference scores at baseline versus at 6 months. The difference between these scores is the mean change reported below. The MD Anderson Symptom Inventory has a scale of 0-10, 0 being not present and 10 being as bad as the patient could imagine. The calculated score change has a range of -10 to 10; -10 being the best. Change in score is calculated as the composite weighted means of symptom severity and interference at 6 months minus the composite weighted means of symptom severity and interference at baseline.
Time frame: Baseline and 6 months post-Baseline
Overall Survival
Clinical Parameter. Here we report the number of patients analyzed for the outcome as well as the number of deaths that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.
Time frame: Through study completion, an average of 1 year
12 Month Cumulative Incidence of Neurologic Death
Clinical parameter to be assessed via review of study visits and medical records indicating cause of death (neurologic versus systemic). Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.
Time frame: Through study completion, an average of 1 year
12 Month Cumulative Incidence of New Brain Metastases
Radiographic assessment of first appearance of new brain metastases. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.
Time frame: Through study completion, an average of 1 year
12 Month Cumulative Incidence of Local Recurrence of Treated Brain Tumor(s)
Radiographic assessment of first local recurrence in the 5-20 brain metastases that were initially treated with radiation. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.
Time frame: Through study completion, an average of 1 year
12 Month Cumulative Incidence of Progressive Intracranial Disease
Radiographic assessment of first instance of progressive intracranial disease. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.
Time frame: Through study completion, an average of 1 year
12 Month Cumulative Incidence of Radiographic Radiation Necrosis
Radiographic assessment of first appearance of radiation necrosis. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.
Time frame: Through study completion, an average of 1 year
12 Month Cumulative Incidence of Leptomeningeal Disease
Radiographic assessment of first appearance of leptomeningeal disease. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.
Time frame: Through study completion, an average of 1 year
12 Month Cumulative Incidence of Dexamethasone Initiation
Assessing time to dexamethasone initiation in patients who were not taking steroids at enrollment. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.
Time frame: Through study completion, an average of 1 year
12 Month Cumulative Incidence of Development of Seizures
Clinical assessment of first post-treatment seizure as assessed during routine study visits and via medical record review. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.
Time frame: Through study completion, an average of 1 year
12 Month Cumulative Incidence of Salvage Stereotactic Radiation
Clinical assessment of first use of salvage stereotactic radiation. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.
Time frame: Through study completion, an average of 1 year
12 Month Cumulative Incidence of Salvage Whole Brain Radiation
Clinical assessment of first use of salvage whole brain radiation with or without hippocampal avoidance. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.
Time frame: Through study completion, an average of 1 year
12 Month Cumulative Incidence of Salvage Neurosurgical Resection
Clinical assessment of first use of neurosurgical resection as salvage therapy. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.
Time frame: Through study completion, an average of 1 year
Mean Barthel Index Score at Baseline
Barthel Index ranges from 0 to 100 with higher scores indicating greater functional independence. A greater difference between the groups indicates greater functional independence in the stereotactic arm. Here we report the mean Barthel Index score at baseline for both arms.
Time frame: Baseline
Change in Barthel Index Score at 4-months and 12-months Post-baseline
Barthel Index ranges from 0 to 100 with higher scores indicating greater functional independence. A greater difference between the groups indicates greater functional independence in the stereotactic arm. Here we report the mean difference (95% Confidence Interval) at each timepoint.
Time frame: 4 Months and 12 months
Karnofsky Performance Status
The Karnofsky Performance Status (KPS) is a tool designed to assess a cancer patient's functional status. Scores range from 0 to 100 with higher scores indicating better function. Scores 90-100 indicate that the patient is independent and can perform daily activities with little to no effort. A score of 80 indicates that the patient can conduct their normal activities with some effort. A score of 70 indicates that a patient can care for themself but cannot carry on normal activities independently. Here we report the least squares mean Karnofsky Performance Score for each arm based on the Karnofsky Performance Status Scale at each timepoint from Baseline to 12 Months post-baseline.
Time frame: Baseline to 12 Months
Hopkins Verbal Learning Test-Revised Total Recall Z-Score at Baseline
Here we report the mean Hopkins Verbal Learning Test-Revised Total Recall (HVLT-R Total Recall) z-score in each arm at baseline. The HVLT-R Total Recall test measures rote verbal learning across 3 trials administered in one sitting. Scores were transformed into z scores. Z scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The Z-Score central value is 0 and represents the population mean. Larger positive z scores indicate better neurocognitive function.
Time frame: Baseline
Change in Hopkins Verbal Learning Test-Revised Total Recall Mean Z-Score at 4-Months and 12-Months Post-baseline
Here we report the mean Hopkins Verbal Learning Test-Revised Total Recall (HVLT-R Total Recall) z-score in each arm at the given timepoint. The HVLT-R Total Recall test measures rote verbal learning across 3 trials administered in one sitting. Scores were transformed into z scores. Z scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The Z-Score central value is 0 and represents the population mean. Larger positive z scores indicate better neurocognitive function.
Time frame: 4 Months and 12 Months
Hopkins Verbal Learning Test-Revised Delayed Recall Z-Score at Baseline
Here we report the mean Hopkins Verbal Learning Test-Revised Delayed Recall Z score at baseline. This test measures delayed memory function. Scores were transformed into z scores. Z scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The Z score central value is 0 and represents the population mean. Larger positive z scores indicate better neurocognitive function.
Time frame: Baseline
Change in Hopkins Verbal Learning Test-Revised Delayed Recall Z Scores at 4 Months and 12 Months
Here we report the mean Hopkins Verbal Learning Test-Revised Delayed Recall Z score at the given timepoint. This test measures delayed memory function. Scores were transformed into z scores. Z scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The Z score central value is 0 and represents the population mean. Larger positive z scores indicate better neurocognitive function.
Time frame: 4 Months and 12 months post-baseline
Hopkins Verbal Learning Test-Revised Recognition Z Score at Baseline
Here we report the mean Hopkins Verbal Learning Test-Revised Recognition z scores in each arm at baseline. The Hopkins Verbal Learning Test - Revised Recognition measures memory storage and recognition. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the populaion mean. Larger, positive z scores indicate better neurocognitive function. Here we report the mean z score in each arm at baseline.
Time frame: Baseline
Change in Hopkins Verbal Learning Test-Revised Recognition Z-score at 4 Months and 12 Months
Here we report the mean Hopkins Verbal Learning Test-Revised Recognition z scores in each arm at the given timepoint. The Hopkins Verbal Learning Test - Revised Recognition measures memory storage and recognition. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the populaion mean. Larger, positive z scores indicate better neurocognitive function. Here we report the mean z score in each arm at the given timepoint.
Time frame: 4 Months and 12 Months post baseline
Trail Making Test A, Z Score at Baseline
Here we report the mean Trail Making Test A z score in each arm at baseline. The Trail Making Test A measures visuomotor processing speed. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the population mean. Larger, positive z scores inicate better visuomotor processing speed.
Time frame: Baseline
Change in Trail Making Test A Z-Score From Baseline at 4 Months and 12 Months
Here we report the mean Trail Making Test A z score in each arm at the given timepoint. The Trail Making Test A measures visuomotor processing speed. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the population mean. Larger, positive z scores inicate better visuomotor processing speed.
Time frame: at 4 Months and 12 Months
Trail Making Test B Z Score at Baseline
Here we report the mean Trail Making Test B z score in each arm at baseline. The Trail Making Test B measures visuomotor processing speed. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the population mean. Larger, positive z scores inicate better visuomotor processing speed.
Time frame: Baseline
Trail Making Test B Z Score at 4 Months and 12 Months Post-baseline
Here we report the mean Trail Making Test B z score in each arm at the given timepoint. The Trail Making Test B measures visuomotor processing speed. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the population mean. Larger, positive z scores inicate better visuomotor processing speed.
Time frame: 4 Months and 12 months post-baseline
Controlled Oral Word Test Z Score at Baseline
Here we report the mean controlled oral word test z score in each arm at baseline. The controlled oral word test (COWAT) measures verbal fluency. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the population mean. A larger positive z score indicates better performance.
Time frame: Baseline
Change in Controlled Oral Word Test Z Score at 4 Months and 12 Months Post Baseline
Here we report the change in mean controlled oral word test z score in each arm at the given timepoints from baseline. The controlled oral word test (COWAT) measures verbal fluency. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the population mean. A larger positive z score indicates better performance.
Time frame: 4 Months and 12 months post baseline
Mini-Mental State Examination Mean at Baseline
Here we report the Mini-Mental State Examination mean in each arm at baseline. The Mini-Mental State Examination measures global cognition on a scale from 0 to 30. Higher scores indicate better perfromance.
Time frame: Baseline
Change in Mini-Mental State Examination Score at 4 Months and 12 Months Post Baseline
Here we report the change in the mean Mini-Mental State Examination z score in each arm at the given timepoints. The Mini-Mental State Examination Scores measures global cognition on a scale from 0 to 30. Test scores were transformed into z scores Larger positive scores indicate better performance. Z scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The Z-Score central value is 0 and represents the population mean. Larger, positive differences indicate better global cognition.
Time frame: 4 Months and 12 months post baseline
Medical Outcomes Study Cognitive Functioning Scale-Revised Normative Score at Baseline
Scores global cognition on a scale from 0 to 100. Higher scores indicate better cognitive function. Scores were transformed into normative scores ranging from 7.51 to 58.61. Larger scores indicate better function.
Time frame: Baseline
Change in Medical Outcomes Study Cognitive Functioning Scale-Revised Normative Scores at 4 Months and 12 Months Post Baseline
Scores global cognition on a scale from 0 to 100. Higher scores indicate better cognitive function. Scores were transformed into normative scores ranging from 7.51 to 58.61. Larger positive differences indicate better function.
Time frame: 4 Months and 12 months post baseline
The study was conducted by Brigham and Women's Hospital/ Dana-Farber Cancer Institute (Boston, MA) and took place at three additional cancer centers: Rhode Island Hospital/Brown University Health (Providence, RI), Milford Regional Medical Center (Milford, MA), and South Shore Health (Weymouth, MA). Patients were enrolled on study between April 2017 and May 2024.
| Milestone | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| Started | 98 | 98 |
| Completed | 86 | 96 |
| Not completed | 12 | 2 |
Questionnaire - MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT). Results reflect patient-reported symptoms. Here they are presented as a mean change: the difference in the weighted mean of symptom severity and interference scores at baseline versus at 6 months. The difference between these scores is the mean change reported below. The MD Anderson Symptom Inventory has a scale of 0-10, 0 being not present and 10 being as bad as the patient could imagine. The calculated score change has a range of -10 to 10; -10 being the best. Change in score is calculated as the composite weighted means of symptom severity and interference at 6 months minus the composite weighted means of symptom severity and interference at baseline.
| Scores on a Scale | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| Change in MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT) Score | 0.7 ± 2.0 | -0.3 ± 1.4 |
Clinical Parameter. Here we report the number of patients analyzed for the outcome as well as the number of deaths that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.
| Percent of participants | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| Overall Survival | 42.8 (32.7 to 52.6) | 41.1 (31.3 to 50.7) |
Clinical parameter to be assessed via review of study visits and medical records indicating cause of death (neurologic versus systemic). Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.
| Percent of participants | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| 12 Month Cumulative Incidence of Neurologic Death | 8.5 (3.9 to 15.3) | 9.4 (4.6 to 16.3) |
Radiographic assessment of first appearance of new brain metastases. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.
| percent of participants | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| 12 Month Cumulative Incidence of New Brain Metastases | 24.2 (16.1 to 33.3) | 45.4 (35.2 to 55.0) |
Radiographic assessment of first local recurrence in the 5-20 brain metastases that were initially treated with radiation. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.
| percent of participants | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| 12 Month Cumulative Incidence of Local Recurrence of Treated Brain Tumor(s) | 39.5 (29.5 to 49.3) | 3.2 (0.8 to 8.3) |
Radiographic assessment of first instance of progressive intracranial disease. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.
| percent of participants | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| 12 Month Cumulative Incidence of Progressive Intracranial Disease | 39.4 (29.4 to 49.2) | 46.4 (36.2 to 56.0) |
Radiographic assessment of first appearance of radiation necrosis. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.
| percent of participants | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| 12 Month Cumulative Incidence of Radiographic Radiation Necrosis | 1.1 (0.1 to 5.3) | 14.8 (8.5 to 22.8) |
Radiographic assessment of first appearance of leptomeningeal disease. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.
| percent of participants | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| 12 Month Cumulative Incidence of Leptomeningeal Disease | 3.2 (0.8 to 8.3) | 8.3 (3.8 to 14.9) |
Assessing time to dexamethasone initiation in patients who were not taking steroids at enrollment. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.
| percent of participants | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| 12 Month Cumulative Incidence of Dexamethasone Initiation | 72.2 (55.7 to 83.4) | 52.2 (36.7 to 65.6) |
Clinical assessment of first post-treatment seizure as assessed during routine study visits and via medical record review. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.
| percent of participants | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| 12 Month Cumulative Incidence of Development of Seizures | 15.8 (9.3 to 24.0) | 11.4 (6.0 to 18.6) |
Clinical assessment of first use of salvage stereotactic radiation. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.
| percent of participants | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| 12 Month Cumulative Incidence of Salvage Stereotactic Radiation | 22.7 (14.7 to 31.7) | 15.5 (9.1 to 23.5) |
Clinical assessment of first use of salvage whole brain radiation with or without hippocampal avoidance. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.
| percent of participants | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| 12 Month Cumulative Incidence of Salvage Whole Brain Radiation | 1.0 (0.1 to 5.1) | 5.1 (1.9 to 10.8) |
Clinical assessment of first use of neurosurgical resection as salvage therapy. Here we report the number of patients analyzed for the outcome as well as the number of events that occurred. We then report the 12 Month Cumulative Incidence with a 95% Confidence Interval.
| percent of participants | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| 12 Month Cumulative Incidence of Salvage Neurosurgical Resection | 6.3 (2.6 to 12.5) | 9.4 (4.6 to 16.3) |
Barthel Index ranges from 0 to 100 with higher scores indicating greater functional independence. A greater difference between the groups indicates greater functional independence in the stereotactic arm. Here we report the mean Barthel Index score at baseline for both arms.
| score on a scale | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| Mean Barthel Index Score at Baseline | 92.2 ± 12.6 | 93.9 ± 10.9 |
Barthel Index ranges from 0 to 100 with higher scores indicating greater functional independence. A greater difference between the groups indicates greater functional independence in the stereotactic arm. Here we report the mean difference (95% Confidence Interval) at each timepoint.
| score on a scale | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| 4 Months | -2.1 ± 13.9 | 1.8 ± 10.5 |
| 12 Months | -4.9 ± 15.6 | 0.3 ± 4.9 |
The Karnofsky Performance Status (KPS) is a tool designed to assess a cancer patient's functional status. Scores range from 0 to 100 with higher scores indicating better function. Scores 90-100 indicate that the patient is independent and can perform daily activities with little to no effort. A score of 80 indicates that the patient can conduct their normal activities with some effort. A score of 70 indicates that a patient can care for themself but cannot carry on normal activities independently. Here we report the least squares mean Karnofsky Performance Score for each arm based on the Karnofsky Performance Status Scale at each timepoint from Baseline to 12 Months post-baseline.
| score on a scale | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| Baseline | 84.67 ± 0.74 | 83.80 ± 0.73 |
| 3 Weeks | 80.96 ± 1.19 | 83.85 ± 0.94 |
| 2 Months | 77.58 ± 1.68 | 84.10 ± 0.93 |
| 4 Months | 75.38 ± 2.03 | 84.89 ± 0.94 |
| 6 Months | 75.86 ± 2.03 | 83.37 ± 1.22 |
| 8 Months | 73.89 ± 2.10 | 85.69 ± 0.96 |
| 10 Months | 77.85 ± 1.84 | 85.62 ± 1.12 |
| 12 Months | 77.27 ± 1.72 | 85.91 ± 1.11 |
Here we report the mean Hopkins Verbal Learning Test-Revised Total Recall (HVLT-R Total Recall) z-score in each arm at baseline. The HVLT-R Total Recall test measures rote verbal learning across 3 trials administered in one sitting. Scores were transformed into z scores. Z scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The Z-Score central value is 0 and represents the population mean. Larger positive z scores indicate better neurocognitive function.
| z score | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| Hopkins Verbal Learning Test-Revised Total Recall Z-Score at Baseline | -1.01 ± 1.30 | -0.99 ± 1.42 |
Here we report the mean Hopkins Verbal Learning Test-Revised Total Recall (HVLT-R Total Recall) z-score in each arm at the given timepoint. The HVLT-R Total Recall test measures rote verbal learning across 3 trials administered in one sitting. Scores were transformed into z scores. Z scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The Z-Score central value is 0 and represents the population mean. Larger positive z scores indicate better neurocognitive function.
| z score | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| 4 Months | -0.04 ± 1.41 | 0.40 ± 1.28 |
| 12 Months | -0.53 ± 1.58 | 0.11 ± 1.22 |
Here we report the mean Hopkins Verbal Learning Test-Revised Delayed Recall Z score at baseline. This test measures delayed memory function. Scores were transformed into z scores. Z scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The Z score central value is 0 and represents the population mean. Larger positive z scores indicate better neurocognitive function.
| z score | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| Hopkins Verbal Learning Test-Revised Delayed Recall Z-Score at Baseline | -1.01 ± 1.30 | -0.99 ± 1.42 |
Here we report the mean Hopkins Verbal Learning Test-Revised Delayed Recall Z score at the given timepoint. This test measures delayed memory function. Scores were transformed into z scores. Z scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The Z score central value is 0 and represents the population mean. Larger positive z scores indicate better neurocognitive function.
| z score | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| 4 Months | -0.04 ± 1.41 | 0.40 ± 1.28 |
| 12 Months | -0.53 ± 1.58 | 0.11 ± 1.22 |
Here we report the mean Hopkins Verbal Learning Test-Revised Recognition z scores in each arm at baseline. The Hopkins Verbal Learning Test - Revised Recognition measures memory storage and recognition. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the populaion mean. Larger, positive z scores indicate better neurocognitive function. Here we report the mean z score in each arm at baseline.
| z score | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| Hopkins Verbal Learning Test-Revised Recognition Z Score at Baseline | -0.49 ± 1.28 | -0.51 ± 1.65 |
Here we report the mean Hopkins Verbal Learning Test-Revised Recognition z scores in each arm at the given timepoint. The Hopkins Verbal Learning Test - Revised Recognition measures memory storage and recognition. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the populaion mean. Larger, positive z scores indicate better neurocognitive function. Here we report the mean z score in each arm at the given timepoint.
| z score | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| 4 Months | 0.03 ± 1.83 | 0.12 ± 1.13 |
| 12 Months | -1.12 ± 2.48 | 0.05 ± 0.88 |
Here we report the mean Trail Making Test A z score in each arm at baseline. The Trail Making Test A measures visuomotor processing speed. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the population mean. Larger, positive z scores inicate better visuomotor processing speed.
| z score | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| Trail Making Test A, Z Score at Baseline | -1.41 ± 4.52 | -0.86 ± 2.81 |
Here we report the mean Trail Making Test A z score in each arm at the given timepoint. The Trail Making Test A measures visuomotor processing speed. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the population mean. Larger, positive z scores inicate better visuomotor processing speed.
| z score | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| 4 Months | -0.15 ± 1.75 | 0.54 ± 2.30 |
| 12 Months | -2.17 ± 6.32 | -0.24 ± 0.89 |
Here we report the mean Trail Making Test B z score in each arm at baseline. The Trail Making Test B measures visuomotor processing speed. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the population mean. Larger, positive z scores inicate better visuomotor processing speed.
| z score | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| Trail Making Test B Z Score at Baseline | -3.40 ± 12.1 | -3.50 ± 6.91 |
Here we report the mean Trail Making Test B z score in each arm at the given timepoint. The Trail Making Test B measures visuomotor processing speed. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the population mean. Larger, positive z scores inicate better visuomotor processing speed.
| z score | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| 4 Months | -0.83 ± 2.65 | 0.92 ± 3.88 |
| 12 Months | -3.53 ± 8.10 | 1.49 ± 5.81 |
Here we report the mean controlled oral word test z score in each arm at baseline. The controlled oral word test (COWAT) measures verbal fluency. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the population mean. A larger positive z score indicates better performance.
| z score | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| Controlled Oral Word Test Z Score at Baseline | -0.62 ± 1.20 | -0.72 ± 1.07 |
Here we report the change in mean controlled oral word test z score in each arm at the given timepoints from baseline. The controlled oral word test (COWAT) measures verbal fluency. Scores were transformed into z scores. z Scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The z score central value is 0 and represents the population mean. A larger positive z score indicates better performance.
| z score | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| 4 Months | -0.39 ± 0.76 | 0.20 ± 0.80 |
| 12 Months | -0.18 ± 0.94 | 0.27 ± 0.72 |
Here we report the Mini-Mental State Examination mean in each arm at baseline. The Mini-Mental State Examination measures global cognition on a scale from 0 to 30. Higher scores indicate better perfromance.
| score on a scale | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| Mini-Mental State Examination Mean at Baseline | 27.6 ± 2.49 | 27.6 ± 2.54 |
Here we report the change in the mean Mini-Mental State Examination z score in each arm at the given timepoints. The Mini-Mental State Examination Scores measures global cognition on a scale from 0 to 30. Test scores were transformed into z scores Larger positive scores indicate better performance. Z scores greater than 2.0 indicate exceptionally high function, between 1.36 and 2.0 indicate above average function, between 0.68 and 1.35 indicate high average function, between -0.67 and 0.67 indicate average function, between -0.68 and -1.35 indicate low average function, between -1.36 and -2.0 indicate below average function, and less than -2.0 indicate exceptionally low. The Z-Score central value is 0 and represents the population mean. Larger, positive differences indicate better global cognition.
| z score | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| 4 Months | -0.11 ± 2.48 | 0.39 ± 2.26 |
| 12 Months | -0.80 ± 2.21 | 0.44 ± 2.75 |
Scores global cognition on a scale from 0 to 100. Higher scores indicate better cognitive function. Scores were transformed into normative scores ranging from 7.51 to 58.61. Larger scores indicate better function.
| score on a scale | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| Medical Outcomes Study Cognitive Functioning Scale-Revised Normative Score at Baseline | 50.5 ± 10.1 | 49.0 ± 10.3 |
Scores global cognition on a scale from 0 to 100. Higher scores indicate better cognitive function. Scores were transformed into normative scores ranging from 7.51 to 58.61. Larger positive differences indicate better function.
| score on a scale | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| 4 Months | -0.38 ± 8.45 | 3.01 ± 9.49 |
| 12 Months | -2.69 ± 9.14 | -0.83 ± 9.60 |
Collected over From enrollment until participant died, withdrew, or was lost to follow up, approximately 24 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Hippocampal-Avoidance Whole Brain Radiation | 85/98 (86.7%) | 25/98 (25.5%) | 90/98 (91.8%) |
| Stereotactic Radiation | 80/98 (81.6%) | 21/98 (21.4%) | 89/98 (90.8%) |
| Event | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| Death NOSGeneral disorders | 12/98 | 4/98 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 4/98 | 6/98 |
| NauseaGastrointestinal disorders | 3/98 | 2/98 |
| FatigueGeneral disorders | 3/98 | 1/98 |
| HeadacheNervous system disorders | 0/98 | 3/98 |
| MyelitisNervous system disorders | 2/98 | 0/98 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/98 | 2/98 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/98 | 0/98 |
| Myocardial infarctionCardiac disorders | 1/98 | 0/98 |
| Abdominal painGastrointestinal disorders | 1/98 | 0/98 |
| Event | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation |
|---|---|---|
| FatigueGeneral disorders | 44/98 | 35/98 |
| NauseaGastrointestinal disorders | 18/98 | 25/98 |
| AnorexiaMetabolism and nutrition disorders | 24/98 | 12/98 |
| HeadacheNervous system disorders | 20/98 | 15/98 |
| Blurred visionEye disorders | 11/98 | 13/98 |
| Back painMusculoskeletal and connective tissue disorders | 4/98 | 13/98 |
| SeizureNervous system disorders | 11/98 | 13/98 |
| Gait disturbanceGeneral disorders | 3/98 | 12/98 |
| Central nervous system necrosisNervous system disorders | 2/98 | 11/98 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 7/98 | 11/98 |
| Age, Customized(Years) | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation | Total |
|---|---|---|---|
| Age | 60 ± 13 | 61 ± 11 | 60.8 ± 12.0 |
| Sex: Female, Male(Participants) | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation | Total |
|---|---|---|---|
| Female | 64 | 65 | 129 |
| Male | 34 | 33 | 67 |
| Race/Ethnicity, Customized(Participants) | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation | Total |
|---|---|---|---|
| Race — Asian | 2 | 6 | 8 |
| Race — Black or African American | 2 | 4 | 6 |
| Race — White | 90 | 86 | 176 |
| Race — More than 1 race | 3 | 0 | 3 |
| Race — Other | 1 | 2 | 3 |
| Race/Ethnicity, Customized(Participants) | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation | Total |
|---|---|---|---|
| Hispanic or Latino Ethnicity | 6 | 1 | 7 |
| Non-Hispanic | 87 | 93 | 180 |
| Unknown | 5 | 4 | 9 |
| Charlson Comorbidity Index(score on a scale) | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation | Total |
|---|---|---|---|
| Median | 0 (0 to 1) | 0 (0 to 1) | 0 (0 to 1) |
| Karnofsky Performance Status(Participants) | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation | Total |
|---|---|---|---|
| 100 | 4 | 2 | 6 |
| 90 | 41 | 45 | 86 |
| 80 | 39 | 38 | 77 |
| 70 | 8 | 12 | 20 |
| Unknown | 6 | 1 | 7 |
| Primary Cancer(Participants) | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation | Total |
|---|---|---|---|
| Non-small cell lung cancer | 43 | 44 | 87 |
| Breast | 23 | 21 | 44 |
| Melanoma | 9 | 9 | 18 |
| Other | 23 | 24 | 47 |
| Neurologic Symptoms(Participants) | Hippocampal-Avoidance Whole Brain Radiation | Stereotactic Radiation | Total |
|---|---|---|---|
| Count of participants | 60 | 60 | 120 |
8 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2017 to primary completion in Nov 2024, 90 months.
Results were first posted in Sep 2026, 1 year 10 months after primary completion.
Of 310 non-industry interventional studies with no phase under Brain Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's 90 months is above that.
Counting every sponsor, half of 321 studies reached it within 64 months; a quarter within 35 and three quarters within 125.
Completion moved once since we started tracking on Sep 25, 2026: Sep 2025 → Sep 2027, on Sep 29, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Aizer AA, Shin KY, Catalano PJ, Ricca I, Johnson M, Benham G, Roper K, Spicer B, Mann E, Nosker J, Parsons MW, Mendu ML, Hepel J, Chipidza F, Krishnan M, Shi D…PubMed 41712219 ↗; 3 more
Aizer AA, Shin KY, Catalano PJ, Ricca I, Johnson M, Benham G, Roper K, Spicer B, Mann E, Nosker J, Parsons MW, Mendu ML, Hepel J, Chipidza F, Krishnan M, Shi D…PubMed 41712219 ↗; 3 more
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Brigham and Women's Hospital →